Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum

Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash runway bolstered by sizable partnership inflows. Leadership repeatedly acknowledged the binary risks of early-stage drug development, but argued that platform scale, discovery efficiency, and repeatable milestones now materially outweigh the funding and execution overhangs.

REC-4881 delivers first AI-enabled clinical proof in FAP

Phase 2 data for REC-4881 in familial adenomatous polyposis marked a key proof point, with a 43% median reduction in polyp burden at the 4 mg once-daily dose and 75% of patients responding. Responses remained durable even after a three-month treatment pause, and the company is now engaging the FDA on a registrational path targeting 2026 while enrolling an 18-plus cohort.

Partnership inflows led by Sanofi validate the model

Recursion has now booked more than $500 million in cumulative upfront and milestone payments from partners, underscoring growing external confidence in its platform. The Sanofi alliance alone has delivered about $134 million so far, and each small-molecule program could generate more than $300 million in future milestones plus tiered royalties that can reach into the double digits.

Cash balance and extended runway to early 2028

The company ended the year with $754 million in cash and updated guidance that its financial runway now stretches into early 2028. Management tied this extension to disciplined expense control and partnership receipts, alongside a framework that probability-weights future milestones when building cash forecasts.

35% operating expense reduction sharpens focus

Operating discipline featured prominently, with Recursion reporting a 35% pro forma year-over-year reduction in operating expenses from 2024 to 2025. Actual spending came in roughly 10% below prior guidance, driven by tighter portfolio focus, leaner G&A, and productivity gains from its AI-enabled platform.

Discovery engine cuts compound needs and timelines

Management emphasized that its AI-driven discovery engine is synthesizing only about 300–330 compounds per program versus roughly 2,500 for industry peers, a roughly 90% reduction. That efficiency has helped compress target-to-advanced-candidate timelines to about 17 months, roughly twice as fast as the 40-plus months often seen across traditional pipelines.

Fast design cycles and promising PI3K preclinical data

For its PI3K H1047 mutant-selective program, Recursion cycled through 13 design rounds and 242 compounds in just 10 months, highlighting rapid iteration. Preclinical models showed dose-dependent tumor regression comparable or better than competitors and, importantly, no hyperglycemia or metabolic issues in both naïve and obese diabetic animals as IND-enabling studies advance toward a 2026 go-or-no-go decision.

Platform scale improving clinical operations

Recursion’s platform now houses over 50 petabytes of multimodal data and integrates information from more than 300 million real-world patient lives. Leveraging this dataset, the firm’s clinical AI tools are improving trial enrollment rates by roughly 1.3 to 1.6 times and can launch studies up to three months earlier by pinpointing optimal sites and patient pools.

Repeatable signals in Sanofi and Roche Genentech deals

Execution on partnered programs was another focus, with five lead packages already delivered and accepted by Sanofi, underscoring the repeatability of Recursion’s discovery output. The Roche Genentech collaboration has also progressed, with two biology maps accepted and now being converted into new therapeutic programs for that partner.

Early-stage pipeline concentration brings binary risk

Despite these advances, management reminded investors that many key assets remain early in development, concentrating risk around upcoming binary events. Critical 2026 milestones include IND-enabling decisions for PI3K and ENPP1 and an early Phase 1 update for RBM39, while several additional data readouts have slipped into 2027, creating a near-term execution overhang.

Sector failure rates temper expectations

Executives repeatedly pointed to the roughly 90% failure rate that characterizes drug discovery across the industry, making clear that most programs historically do not reach approval. While Recursion believes its AI-enabled approach improves odds and speed, it stressed that no platform can fully escape the probabilistic nature of biotech R&D.

Tolerability still needs to be proven in the clinic

Several of Recursion’s targets, including MALT1, LSD1, and PI3K, have a track record of tolerability issues in the broader field, particularly around safety and side effects. The company has engineered its molecules to mitigate these concerns but acknowledged that only clinical data can validate whether the safety profile is meaningfully improved.

Dependence on future milestones to bridge the gap

The extended runway to early 2028 partly relies on expected milestone receipts from existing and future collaborations, which remain uncertain by nature. While management probability-weights these inflows in cash planning, the business still depends heavily on continued partner success to avoid tapping capital markets or cutting deeper into the pipeline.

Runway limits long-term visibility despite efficiencies

Even with $754 million in cash on hand and sizable cost reductions, Recursion’s visibility only extends a few years absent new capital or commercial revenue. Investors must weigh the company’s accelerated R&D engine and partnership leverage against the finite runway and the time it may take for any single asset to reach meaningful sales.

NVIDIA divestment raises perception risk, not strategic

An investor question highlighted that NVIDIA has exited its equity stake according to filings, potentially creating headline pressure around sentiment. Management framed this as a portfolio decision by NVIDIA and said the underlying technical collaboration remains intact, but acknowledged that such moves can influence how the wider market perceives the story.

Guidance and pipeline milestones frame the next phase

Looking ahead, Recursion expects 2026 cash operating expenses to stay below $390 million on a non-GAAP basis, supporting its extended runway into early 2028 as platform efficiencies deepen. Key upcoming milestones include FDA dialogue for REC-4881 in 2026, early RBM39 Phase 1 safety and PK data that same year, go-or-no-go calls for PI3K and ENPP1 in the second half of 2026, and additional REC-4881 plus CDK7 combination data in 2027.

Recursion’s earnings call painted a picture of a company moving from AI promise toward clinical substance, anchored by early proof-of-concept, faster discovery cycles, and durable partner demand. Yet with most value still tied to high-risk, early-stage assets and a runway that ends before potential commercialization, investors will need to balance the strong platform narrative against the inherent volatility of biotech execution.